20 YEARS OF PROFESSIONAL & DEDICATED SERVICE TO GLOBAL CUSTOMERS

Custom Manufacturing, Project Outsourcing, your Trusted Partner from China

Navigating the Safety of Lenalidomide: Understanding Risks and Mitigation Strategies

While Lenalidomide is a highly effective treatment for several serious hematological conditions, its use is accompanied by significant safety considerations that necessitate rigorous management protocols. Understanding these risks is paramount for both healthcare providers and patients.

The most prominent safety concern associated with Lenalidomide is its teratogenicity, a risk shared with its predecessor, thalidomide. Exposure during pregnancy can lead to severe birth defects or fetal death. Consequently, strict Risk Evaluation and Mitigation Strategies (REMS) programs are in place to prevent fetal exposure. These programs mandate comprehensive patient and physician education, the use of effective contraception by both male and female patients of reproductive potential, and regular pregnancy testing for women. The Lenalidomide teratogenicity risk underscores the absolute necessity of adhering to all prescribed safety guidelines.

Beyond teratogenicity, Lenalidomide can cause significant hematological toxicities, including neutropenia (low white blood cell count) and thrombocytopenia (low platelet count). These conditions increase the risk of infection and bleeding, respectively. Regular blood monitoring is essential to detect and manage these adverse effects promptly. Furthermore, there is an increased risk of venous thromboembolism (blood clots) in patients taking Lenalidomide, particularly when used in combination with other medications. Prophylactic anticoagulant therapy is often prescribed to mitigate this risk.

NINGBO INNO PHARMCHEM CO.,LTD. is committed to ensuring the quality and safety of its pharmaceutical products. Adherence to all regulatory requirements and continuous monitoring of product safety are integral to our operations. Patients and healthcare professionals must remain vigilant and informed about the potential Lenalidomide side effects to ensure optimal treatment outcomes while minimizing risks.

Manufacturing Facilities

NINGBO INNO PHARMCHEM CO.,LTD. was established in 2007. It is committed to the R&D, production and sales of raw materials, pharmaceutical intermediates and fine chemicals. We striving to create a high-efficiency and high-quality integrated chemical service platform to better serve domestic and foreign customers.

Professional Export Experience

to Global Customers

WHY CHOSE US?

1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;

2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;

3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).

FAQ

  • A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.

  • A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.

  • A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.

CONTACT US
Should you need to contact us; you may call during regular business hours, Monday through Friday, 8am – 6 pm.
NINGBO INNO PHARMCHEM CO.,LTD.
Address: No.163 Ruiqing Rd.,Ningbo 315000 China
Phone: 86-574-87319282
Fax: 86-574-27912196
SEND US AN EMAIL

NAME*

EMAIL*

COMPANY

COUNTRY*

MESSAGE*

Previous: The Multifaceted Mechanism of Lenalidomide: How it Fights Hematological Malignancies

Next: Lenalidomide in Clinical Practice: Applications in Multiple Myeloma and Beyond

All Rights Reserved